Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy D Warner

Showing results (1-10 of 115) with videos related to

Pageof 12
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|November 20, 2002
Origins of prostaglandin E2: involvements of cyclooxygenase (COX)-1 and COX-2 in human and rat systemsFrancesco Giuliano, Timothy D Warner
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 5, 2003
PPARgamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonistDavid Bishop-Bailey, Timothy D Warner
Lancet (London, England)|January 22, 2008
COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugsTimothy D Warner, Jane A Mitchell
Nature Reviews. Drug Discovery|February 18, 2006
COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugsJane A Mitchell, Timothy D Warner
Proceedings of the National Academy of Sciences of the United States of America|February 26, 2013
Reply to Ricciotti et al.: Evidence for vascular COX isoformsJane A Mitchell, Timothy D Warner
Clinical Science (London, England : 1979)|July 10, 2003
HIF, stretching to get control of VEGFTimothy D Warner, Jane A Mitchell
Pharmacology & Therapeutics|August 7, 2018
Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacyRebecca B Knowles, Timothy D Warner
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 1, 2004
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinicTimothy D Warner, Jane A Mitchell
Proceedings of the National Academy of Sciences of the United States of America|July 30, 2003
Nonsteroidal antiinflammatory drugs inhibiting prostanoid efflux: as easy as ABC?Timothy D Warner, Jane A Mitchell
Proceedings of the National Academy of Sciences of the United States of America|October 11, 2002
Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?Timothy D Warner, Jane A Mitchell
Pageof 12

Showing results (1-10 of 115) with videos related to

Sort By:
Pageof 12
The Journal of Pharmacology and Experimental Therapeutics|November 20, 2002
Origins of prostaglandin E2: involvements of cyclooxygenase (COX)-1 and COX-2 in human and rat systemsFrancesco Giuliano, Timothy D Warner
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 5, 2003
PPARgamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonistDavid Bishop-Bailey, Timothy D Warner
Lancet (London, England)|January 22, 2008
COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugsTimothy D Warner, Jane A Mitchell
Nature Reviews. Drug Discovery|February 18, 2006
COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugsJane A Mitchell, Timothy D Warner
Proceedings of the National Academy of Sciences of the United States of America|February 26, 2013
Reply to Ricciotti et al.: Evidence for vascular COX isoformsJane A Mitchell, Timothy D Warner
Clinical Science (London, England : 1979)|July 10, 2003
HIF, stretching to get control of VEGFTimothy D Warner, Jane A Mitchell
Pharmacology & Therapeutics|August 7, 2018
Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacyRebecca B Knowles, Timothy D Warner
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 1, 2004
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinicTimothy D Warner, Jane A Mitchell
Proceedings of the National Academy of Sciences of the United States of America|July 30, 2003
Nonsteroidal antiinflammatory drugs inhibiting prostanoid efflux: as easy as ABC?Timothy D Warner, Jane A Mitchell
Proceedings of the National Academy of Sciences of the United States of America|October 11, 2002
Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?Timothy D Warner, Jane A Mitchell
Pageof 12